Dr. Todd Morgan

I mean, I've only tackled one that's very memorable of when the node was in that kind of perirectal fat and just trying to, you know, so we've learned based on PET imaging that maybe about 10% of lymph node metastases go that direction. Different nodal chain and like finding that little pea-sized thing in there was unpleasant. We got it out, but we're like, by the grace of God, we got it out.

I mean, I've only tackled one that's very memorable of when the node was in that kind of perirectal fat and just trying to, you know, so we've learned based on PET imaging that maybe about 10% of lymph node metastases go that direction. Different nodal chain and like finding that little pea-sized thing in there was unpleasant. We got it out, but we're like, by the grace of God, we got it out.

Did the patient benefit from it? That's the question. Well, when you look at published series, really, it does not look like it. All of these patients recur. This was, you know, really, I think, nice study published in European Urology four or so years ago, I think. Bravi was the lead author. It just shows that all these patients recur.

Did the patient benefit from it? That's the question. Well, when you look at published series, really, it does not look like it. All of these patients recur. This was, you know, really, I think, nice study published in European Urology four or so years ago, I think. Bravi was the lead author. It just shows that all these patients recur.

Did the patient benefit from it? That's the question. Well, when you look at published series, really, it does not look like it. All of these patients recur. This was, you know, really, I think, nice study published in European Urology four or so years ago, I think. Bravi was the lead author. It just shows that all these patients recur.

And so in the absence of better data, data was convinced that it wasn't making a difference based on data like that and stopped doing it. And in the guidelines, we do include it as something to have on the table in, you know, select circumstances. But I'm actually looking at the text here. It's right.

And so in the absence of better data, data was convinced that it wasn't making a difference based on data like that and stopped doing it. And in the guidelines, we do include it as something to have on the table in, you know, select circumstances. But I'm actually looking at the text here. It's right.

And so in the absence of better data, data was convinced that it wasn't making a difference based on data like that and stopped doing it. And in the guidelines, we do include it as something to have on the table in, you know, select circumstances. But I'm actually looking at the text here. It's right.

However, these patients should be counseled regarding the uncertain oncologic benefit from surgery in this setting. And I'd say to put that mildly, conditional recommendation evidence level grade C. Yeah. I don't know many folks are still doing it.

However, these patients should be counseled regarding the uncertain oncologic benefit from surgery in this setting. And I'd say to put that mildly, conditional recommendation evidence level grade C. Yeah. I don't know many folks are still doing it.

However, these patients should be counseled regarding the uncertain oncologic benefit from surgery in this setting. And I'd say to put that mildly, conditional recommendation evidence level grade C. Yeah. I don't know many folks are still doing it.

I totally agree. Yeah. It was worth a try, I think. And again, people, I mean, there were people who did a lot of these and I'm sure did an amazing job and they published their data, which is awesome.

I totally agree. Yeah. It was worth a try, I think. And again, people, I mean, there were people who did a lot of these and I'm sure did an amazing job and they published their data, which is awesome.

I totally agree. Yeah. It was worth a try, I think. And again, people, I mean, there were people who did a lot of these and I'm sure did an amazing job and they published their data, which is awesome.

I don't think so. I mean, the most important thing that we can do is talk to our patients, help them understand what's going on, and get them to a radiation oncologist. Like, it's still something that we don't do enough of, and we just, we got to do it. There's really strong data now to support getting a PSMA PET in the setting. I think the coverage is not an issue.

I don't think so. I mean, the most important thing that we can do is talk to our patients, help them understand what's going on, and get them to a radiation oncologist. Like, it's still something that we don't do enough of, and we just, we got to do it. There's really strong data now to support getting a PSMA PET in the setting. I think the coverage is not an issue.

I don't think so. I mean, the most important thing that we can do is talk to our patients, help them understand what's going on, and get them to a radiation oncologist. Like, it's still something that we don't do enough of, and we just, we got to do it. There's really strong data now to support getting a PSMA PET in the setting. I think the coverage is not an issue.

Around here, it's happening throughout the state, and so I'm really encouraged by that. I suspect in California, it's the same. Radiation or salvage treatment informed by PET scans is well supported now. And that's the EMPIRE study, EMPIRE-1 study, where patients were randomized to either a PET-informed or non-PET-informed strategy. And the PET-informed strategy worked better.

Around here, it's happening throughout the state, and so I'm really encouraged by that. I suspect in California, it's the same. Radiation or salvage treatment informed by PET scans is well supported now. And that's the EMPIRE study, EMPIRE-1 study, where patients were randomized to either a PET-informed or non-PET-informed strategy. And the PET-informed strategy worked better.

Around here, it's happening throughout the state, and so I'm really encouraged by that. I suspect in California, it's the same. Radiation or salvage treatment informed by PET scans is well supported now. And that's the EMPIRE study, EMPIRE-1 study, where patients were randomized to either a PET-informed or non-PET-informed strategy. And the PET-informed strategy worked better.